Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
“We look forward to the presentation of these new data evaluating the ability of our non-invasive Percepta Nasal Swab test to accurately assess lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden,” said
Following are details of the abstract accepted for a poster presentation at ATS 2022:
Date/Time: |
|
|
Title: |
A Nasal Genomic Classifier for Assessing Risk of Malignancy In Lung Nodules Demonstrates Similar Performance In Patients that Meet Screening Criteria for High Baseline Risk and Those Who Do Not, Poster #217 |
|
Presenter: |
|
|
Location: |
|
|
Poster Discussion B30 |
Percepta Nasal Swab is a first-of-its-kind genomic test developed for use in current and former smokers with lung nodules. The test is designed to help physicians more accurately, quickly and confidently assess lung cancer risk among these individuals so that those whose lung nodules are benign may avoid unnecessary invasive procedures, and patients whose nodules are likely cancerous may proceed to further diagnostic work-up and, if necessary, treatment or surgery per guideline recommendations. The test’s performance in classifying lung cancer risk has previously been validated, and it is being made available to a limited number of sites as the company develops the clinical utility evidence to support reimbursement.
Title: |
Integrating novel genomic data to improve ILD diagnostic and prognostic confidence |
|
Presenter: |
|
|
Date/Time: |
|
|
Location: |
|
|
Title: |
Integrating the Percepta Genomic Sequencing Classifier for lung nodule risk stratification |
|
Presenters: |
|
|
Date/Time: |
|
|
Location: |
|
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the Percepta Nasal Swab test. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," “suggest,” "may," "will" “prospective” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. An example of a forward looking statement include, among others, that the Percepta Nasal Swab test is designed to help physicians more accurately, quickly and confidently assess lung cancer risk among these individuals so that those whose lung nodules are benign may avoid unnecessary invasive procedures Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006197/en/
Investors:
investors@veracyte.com
619-393-1545
Media:
Vice President of
tracy.morris@veracyte.com
650-380-4413
Source: